Back to today’s briefing

Story perspectives

Gene Therapy Breakthroughs: CAR-T Approvals Spark Renewed Investment

11/27/2025

50 11 Full Breakdown

Summary

Story summary

In vivo gene therapy advances show progress, with Hrain Biotechnology’s chimeric antigen receptor T-cell (CAR-T) therapy approved in China.
Precigen’s RNA therapy is approved in the United States.
Trial initiations slow, yet over 3,200 active studies remain.
Deal activity reached 99 transactions, signaling renewed CAR investment.
Pancreatic cancer is now among the top five rare targets, and non-oncology gene therapy programs have risen to 42%.

1 of 1

Story summary

In vivo gene therapy advances show progress, with Hrain Biotechnology’s chimeric antigen receptor T-cell (CAR-T) therapy approved in China.
Precigen’s RNA therapy is approved in the United States.
Trial initiations slow, yet over 3,200 active studies remain.
Deal activity reached 99 transactions, signaling renewed CAR investment.
Pancreatic cancer is now among the top five rare targets, and non-oncology gene therapy programs have risen to 42%.